A new oral SERD drug, SAR439859, shown the anti-tumor activity in ER+/Her2- breast cancer

Breast cancer is the most common cancer in women. Hormone therapy is the major treatment option for patients with estrogen receptor-positive (ER+) and Her2-negative (Her2-) breast cancer.

More >>